ProKidney Corp Company Leadership
| PROK Stock | USD 2.02 0.04 2.02% |
ProKidney Corp employs about 204 people. The company is managed by 21 executives with a total tenure of roughly 476 years, averaging almost 22.0 years of service per executive, having 9.71 employees per reported executive. Inspection of ProKidney Corp's management performance can provide insight into the company performance.
ProKidney | Build AI portfolio with ProKidney Stock |
ProKidney Corp Management Team Effectiveness
The company has return on total asset (ROA) of (0.2585) % which means that it has lost $0.2585 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4181) %, meaning that it created substantial loss on money invested by shareholders. ProKidney Corp's management efficiency ratios could be used to measure how well ProKidney Corp manages its routine affairs as well as how well it operates its assets and liabilities.ProKidney Corp owns a total of 141.55 Million outstanding shares. ProKidney Corp has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
ProKidney Corp Workforce Comparison
ProKidney Corp is regarded second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,357. ProKidney Corp retains roughly 204 in number of employees claiming about 15% of equities under Health Care industry.
ProKidney Corp Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProKidney Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProKidney Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ProKidney Corp insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Legorreta Pablo G. 20 hours ago Acquisition by Legorreta Pablo G. of 125862 shares of ProKidney Corp at 0.72 subject to Rule 16b-3 | ||
Cowen Aaron over a week ago Insider Trading | ||
Pereira Brian Jg over three months ago Disposition of 27595 shares by Pereira Brian Jg of ProKidney Corp at 2.7234 subject to Rule 16b-3 | ||
Darin Weber over three months ago Disposition of 84103 shares by Darin Weber of ProKidney Corp at 1.73 subject to Rule 16b-3 | ||
Cowen Aaron over six months ago Insider Trading | ||
Legorreta Pablo G. over six months ago Acquisition by Legorreta Pablo G. of 5289055 shares of ProKidney Corp subject to Rule 16b-3 | ||
Legorreta Pablo G. over six months ago Disposition of 3823996 shares by Legorreta Pablo G. of ProKidney Corp subject to Rule 16b-3 | ||
Lotvin Alan over six months ago Acquisition by Lotvin Alan of 125862 shares of ProKidney Corp at 0.72 subject to Rule 16b-3 |
ProKidney Corp Notable Stakeholders
A ProKidney Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ProKidney Corp often face trade-offs trying to please all of them. ProKidney Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ProKidney Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Dr DVM | Founder Advisor | Profile | |
| Bruce MD | CEO Director | Profile | |
| Ulrich Ernst | EVP Technology | Profile | |
| Aparna MD | VP Development | Profile | |
| Joseph MD | VP Devel | Profile | |
| Ashley Johns | VP Operations | Profile | |
| Carla Poulson | Chief Officer | Profile | |
| Lucio Tozzi | Senior Operations | Profile | |
| James CPA | Chief Officer | Profile | |
| Richard Williams | Senior Technology | Profile | |
| Kerry MD | VP Affairs | Profile | |
| Anu Biswas | Senior Operations | Profile | |
| Mary Weger | Chief Officer | Profile | |
| Esq JD | Chief Sec | Profile | |
| Darin Weber | VP Devel | Profile | |
| Deepak Jain | Chief Officer | Profile | |
| Emily Butler | Senior Biometric | Profile | |
| Nikhil PereiraKamath | Chief Officer | Profile | |
| Pharm MPH | Senior Relations | Profile | |
| Libbie MD | Chief Officer | Profile | |
| MPH MD | Senior Procedures | Profile |
About ProKidney Corp Management Performance
The success or failure of an entity such as ProKidney Corp often depends on how effective the management is. ProKidney Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ProKidney management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ProKidney management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Prokidney Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
ProKidney Corp Workforce Analysis
Traditionally, organizations such as ProKidney Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ProKidney Corp within its industry.ProKidney Corp Manpower Efficiency
Return on ProKidney Corp Manpower
| Revenue Per Employee | 373 | |
| Revenue Per Executive | 3.6K | |
| Net Loss Per Employee | 800.7K | |
| Net Loss Per Executive | 7.8M | |
| Working Capital Per Employee | 1.8M | |
| Working Capital Per Executive | 17.1M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. Anticipated expansion of ProKidney directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ProKidney Corp assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate ProKidney Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating ProKidney Corp's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause ProKidney Corp's market price to deviate significantly from intrinsic value.
It's important to distinguish between ProKidney Corp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProKidney Corp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, ProKidney Corp's market price signifies the transaction level at which participants voluntarily complete trades.